Premium Nahrungsergänzungsmittel | artgerecht

Estrogen Receptor Analysis – Meaning & Therapy

Estrogen receptor analysis is a diagnostic test that determines whether tumor cells carry estrogen receptors. The result plays a key role in guiding cancer treatment decisions.

Regular tips about health Regular tips about health

Things worth knowing about "Estrogen Receptor Analysis"

Estrogen receptor analysis is a diagnostic test that determines whether tumor cells carry estrogen receptors. The result plays a key role in guiding cancer treatment decisions.

What Is Estrogen Receptor Analysis?

Estrogen receptor analysis (ER analysis) is a laboratory diagnostic procedure used to determine whether cancer cells – most commonly in breast cancer – carry estrogen receptors (ER) on their surface or within their nuclei. Estrogen receptors are protein molecules that bind the hormone estrogen. When a tumor is estrogen receptor-positive (ER+), it means that hormonal signaling can drive tumor growth. This information is critical for planning the most effective cancer treatment.

Clinical Applications

Estrogen receptor analysis is used in several clinical contexts:

Breast cancer: Routinely performed for every newly diagnosed breast cancer case
Endometrial cancer: To assess the hormonal influence on the tumor
Ovarian cancer: In selected cases to guide therapy planning
Metastatic disease: To reassess receptor status in distant metastases, as it may change over time

How Is the Analysis Performed?

Estrogen receptor analysis is typically performed on a tissue sample (biopsy) obtained during tumor surgery or a core needle biopsy. The tissue is processed in a pathology laboratory and examined using specialized techniques:

Immunohistochemistry (IHC)

The most widely used method is immunohistochemistry. Labeled antibodies that specifically bind to estrogen receptors are applied to tissue sections. Under a microscope, a pathologist can determine how many tumor cells carry receptors and how strongly they are expressed. Results are typically reported as the percentage of positive cells and the staining intensity, often summarized using the Allred Score or H-Score.

Molecular Methods

In certain cases, molecular techniques such as RT-PCR (reverse transcriptase polymerase chain reaction) or gene expression profiling may be used to assess estrogen receptor status at the RNA level.

Interpretation of Results

The results of estrogen receptor analysis are classified into two main categories:

ER-positive (ER+): Tumor cells carry estrogen receptors. The tumor is likely to respond to hormonal influences and can be treated with endocrine (hormone-blocking) therapy. Approximately 70–80% of all breast cancers are ER-positive.
ER-negative (ER-): Tumor cells carry no or very few estrogen receptors. Hormone therapy is not effective in this case; other treatment approaches such as chemotherapy or targeted therapies are used instead.

Relevance for Treatment Planning

The result of estrogen receptor analysis has direct implications for treatment:

For ER-positive tumors, endocrine therapy is commonly used. This includes medications such as tamoxifen (which blocks estrogen receptors) or aromatase inhibitors (which reduce estrogen production in the body). These therapies can significantly lower the risk of recurrence.
For ER-negative tumors, endocrine therapy is not indicated. Treatment is guided by other tumor characteristics such as HER2 status or the proliferation index Ki-67.
Estrogen receptor analysis is often performed together with progesterone receptor (PR) testing and HER2 status assessment – collectively referred to as the hormone receptor status. This combination enables precise tumor classification and individualized treatment decisions.

Changes in Receptor Status Over Time

It is important to note that estrogen receptor status can change during the course of the disease or following treatment. For this reason, a repeat biopsy and receptor analysis are often recommended at the time of relapse or when new metastases appear, in order to adapt the therapy accordingly.

References

Hammond ME et al. - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology, 2010.
Leitlinienprogramm Onkologie (German Cancer Society, German Cancer Aid, AWMF) - S3 Guideline for Early Detection, Diagnosis, Therapy and Follow-up of Breast Cancer, 2021. Available at: https://www.leitlinienprogramm-onkologie.de
World Health Organization (WHO) - Breast Tumours. WHO Classification of Tumours, 5th Edition, Volume 2. IARC Press, Lyon, 2019.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.